HIV-AIDS
The World Health Organization (WHO) has reported that 40 million people are living with HIV/AIDS worldwide and that 3 million die annually from the disease. With almost 65 percent of new HIV infections occurring in remote parts of the world, such as sub-Saharan Africa, the ability to monitor disease progression and provide adequate treatment efficiently and cost-effectively is essential. Monitoring total and fractional T cell counts in patients with HIV is a standard way to determine when to begin antiretroviral therapy as well as when to initiate treatment for opportunistic infections. Further, monitoring CD4 T cell counts is an established way to determine progression of HIV/AIDS.
Proper health care requires that infected individuals be tested at least twice per year and more ideally, four times per year, depending upon their clinical symptoms. With rising health care costs, concerns over the spread of HIV infection, and necessity to make good therapy decisions, the need for cost-effective CD4 testing has increased. Guava® CD4 T-cell Assay Systems were designed to easily monitor T-cell counts in immunodeficient patients at a reasonable cost.
For more information about how a Guava System can support treatment of HIV/AIDS, please visit the following links:
For more information about how a Guava System can support HIV/AIDS research efforts, please visit the following links:
Key references
WHO Report on the Global AIDS Epidemic. 2006; pp 8, 15,
Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. October 10, 2006.
Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: Toward universal access. WHO. 2006 revision; pp 17. | 
